224 related articles for article (PubMed ID: 9313662)
1. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group.
Klippel KF; Hiltl DM; Schipp B
Br J Urol; 1997 Sep; 80(3):427-32. PubMed ID: 9313662
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Nordling J
BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
[TBL] [Abstract][Full Text] [Related]
3. [Clinical effects of beta-sitosterol (phytosterol) on benign prostatic hyperplasia: preliminary study].
Kobayashi Y; Sugaya Y; Tokue A
Hinyokika Kiyo; 1998 Dec; 44(12):865-8. PubMed ID: 10028431
[TBL] [Abstract][Full Text] [Related]
4. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Stief CG; Porst H; Neuser D; Beneke M; Ulbrich E
Eur Urol; 2008 Jun; 53(6):1236-44. PubMed ID: 18281145
[TBL] [Abstract][Full Text] [Related]
5. A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency.
Sudeep HV; Thomas JV; Shyamprasad K
BMC Urol; 2020 Jul; 20(1):86. PubMed ID: 32620155
[TBL] [Abstract][Full Text] [Related]
6. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group.
Berges RR; Windeler J; Trampisch HJ; Senge T
Lancet; 1995 Jun; 345(8964):1529-32. PubMed ID: 7540705
[TBL] [Abstract][Full Text] [Related]
7. [Fushile: a safe and effective therapeutic for benign prostatic hyperplasia].
Shang XJ; Liu ZY; Liu ZF; Sun YH; Huang YF
Zhonghua Nan Ke Xue; 2008 Mar; 14(3):227-30. PubMed ID: 18488335
[TBL] [Abstract][Full Text] [Related]
8. [Clinical study of Eviprostat for the treatment of benign prostatic hyperplasia].
Song Y; Li NC; Wang XF; Ma LL; Wan B; Hong BF; Na YQ
Zhonghua Nan Ke Xue; 2005 Sep; 11(9):674-6. PubMed ID: 16209208
[TBL] [Abstract][Full Text] [Related]
9. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Roehrborn CG
BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
Chung BH; Hong SJ
BJU Int; 2006 Jan; 97(1):90-5. PubMed ID: 16336335
[TBL] [Abstract][Full Text] [Related]
11. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.
Barkin J; Roehrborn CG; Siami P; Haillot O; Morrill B; Black L; Montorsi F;
BJU Int; 2009 Apr; 103(7):919-26. PubMed ID: 19239460
[TBL] [Abstract][Full Text] [Related]
12. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
Gratzke P; Kirby RS
Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
[TBL] [Abstract][Full Text] [Related]
13. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up.
Berges RR; Kassen A; Senge T
BJU Int; 2000 May; 85(7):842-6. PubMed ID: 10792163
[TBL] [Abstract][Full Text] [Related]
14. [A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia].
Xu J; Qian WQ; Song JD
Zhonghua Nan Ke Xue; 2008 Jun; 14(6):533-7. PubMed ID: 18649754
[TBL] [Abstract][Full Text] [Related]
15. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial.
Colli E; Rigatti P; Montorsi F; Artibani W; Petta S; Mondaini N; Scarpa R; Usai P; Olivieri L; Maggi M;
Eur Urol; 2006 Jan; 49(1):82-6. PubMed ID: 16310924
[TBL] [Abstract][Full Text] [Related]
16. [Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
Fourcade RO
Prog Urol; 2000 Apr; 10(2):246-53. PubMed ID: 10857142
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study.
Falahatkar S; Mokhtari G; Pourreza F; Asgari SA; Kamran AN
Urology; 2008 Oct; 72(4):813-6. PubMed ID: 18692876
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement.
Mills IW; Crossland A; Patel A; Ramonas H
Eur Urol; 2007 Aug; 52(2):503-9. PubMed ID: 17343981
[TBL] [Abstract][Full Text] [Related]
19. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
20. The natural history of benign prostatic hyperplasia.
Fitzpatrick JM
BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
